Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant ; volume:21 ; number:1 ; day:8 ; month:5 ; year:2023 ; pages:1-9 ; date:12.2023
Health and quality of life outcomes ; 21, Heft 1 (8.5.2023), 1-9, 12.2023
- Urheber
-
Jamieson, Carol
Popova, Vanina
Daly, Ella
Cooper, Kimberly
Drevets, Wayne C.
Rozjabek, Heather M.
Singh, Jaskaran
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12955-023-02113-1
- URN
-
urn:nbn:de:101:1-2023090708285194491901
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jamieson, Carol
- Popova, Vanina
- Daly, Ella
- Cooper, Kimberly
- Drevets, Wayne C.
- Rozjabek, Heather M.
- Singh, Jaskaran
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Is (S)-norketamine an alternative antidepressant for esketamine?
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Personalized use of ketamine and esketamine for treatment-resistant depression
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
CircKat6b Mediates the Antidepressant Effect of Esketamine by Regulating Astrocyte Function
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Genome-wide association studies of antidepressant class response and treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Is (S)-norketamine an alternative antidepressant for esketamine?
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Personalized use of ketamine and esketamine for treatment-resistant depression
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
CircKat6b Mediates the Antidepressant Effect of Esketamine by Regulating Astrocyte Function
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Genome-wide association studies of antidepressant class response and treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Is (S)-norketamine an alternative antidepressant for esketamine?
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Personalized use of ketamine and esketamine for treatment-resistant depression
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
CircKat6b Mediates the Antidepressant Effect of Esketamine by Regulating Astrocyte Function
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Genome-wide association studies of antidepressant class response and treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial